ProtoKinetix’ AAGP™ is Critical for Stem Cell Therapy

PROTOKINETIX INC. (PKTX: OTCBB)
Vancouver, British Columbia, February 19, 2009


Protokinetix’ (PKTX) results over the last 2-years have clearly shown the vital role that AAGP™ can play in this exciting disease treatment arena. Support for stem cell research has never been stronger and continues to grow. This growth will accelerate as successful results are announced.

One of the most important ingredients for the success of this therapy is the recovery of the maximum number of viable stem cells after storage. These extremely delicate cells typically have a very low yield after cryopreservation. AAGP™ testing that has been conducted on stem cell preservation at all temperatures has shown an impressive increase in survivability and viability.

In summary, over the past 24-months, AAGP™ has demonstrated a remarkable increase in viable cell recovery at temperatures ranging from -196?C (cryopreservation) all the way to 37?C (body temperature). These results have been consistent regardless of the source of the stem cells. As an example, AAGP™ has been independently tested as a protective agent in the cryopreservation (-196?C) and subsequent thawing of umbilical cord blood in low concentrations of AAGP™ (4mg/ml). The resultant analysis revealed a more than double average increase over the control group (cells not protected with AAGP™) in the yield, following thawing.
About ProtoKinetix

ProtoKinetix Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the Company about the broad range of applications for AAGP™ products. For more detailed information, visit our website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Ross L. Senior, President and CEO


Company Office:
ProtoKineitx Inc.
Suite 1500 - 885 West Georgia Street
Vancouver, BC
V6C 3E8

At ProtoKinetix:
Blair Henderson
604-687-9887
Email: info@protokinetix.com